Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Martínez-Cibrián N, Ortiz-Maldonado V, Español-Rego M, Blázquez A, Cid J, Lozano M, Magnano L, Giné E, Correa JG, Mozas P, Rodríguez-Lobato LG, Rivero A, Montoro-Lorite M, Ayora P, Navarro S, Alserawan L, González-Navarro EA, Castellà M, Sánchez-Castañón M, Cabezón R, Benítez-Ribas D, Setoaín X, Rodríguez S, Brillembourg H, Varea S, Olesti E, Guillén E, Sáez-Peñataro J, de Larrea CF, López-Guillermo A, Pascal M, Urbano-Ispizua Á, Juan M, Delgado J. Martínez-Cibrián N, et al. Among authors: juan m. Br J Haematol. 2024 Feb;204(2):525-533. doi: 10.1111/bjh.19170. Epub 2023 Oct 31. Br J Haematol. 2024. PMID: 37905734
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV).
Sánchez-Guijo F, Avendaño-Solá C, Badimón L, Bueren JA, Canals JM, Delgadillo J, Delgado J, Eguizábal C, Fernández-Santos ME, García-Olmo D, González-Aseguinolaza G, Juan M, Martín F, Mata R, Montserrat N, Pérez-Martínez A, Pérez-Simón JA, Prósper F, Urbano-Ispizua Á, Zapata AG, Sureda A, Moraleda JM. Sánchez-Guijo F, et al. Among authors: juan m. Bone Marrow Transplant. 2023 Jun;58(6):727-728. doi: 10.1038/s41409-023-01962-0. Epub 2023 Mar 25. Bone Marrow Transplant. 2023. PMID: 36966215 Free PMC article. No abstract available.
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N, Calderón H, Martinez R, Vazquez M, Gómez-Caverzaschi V, Pascal M, Araújo O, Juan M, González-Navarro EA, Hernández-Rodríguez J. Egri N, et al. Among authors: juan m. Front Immunol. 2023 Apr 27;14:1146841. doi: 10.3389/fimmu.2023.1146841. eCollection 2023. Front Immunol. 2023. PMID: 37180097 Free PMC article.
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldés A, et al. Among authors: juan m. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. Lancet Oncol. 2023. PMID: 37414060 Free article.
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
Garcia-Pouton N, Ortiz-Maldonado V, Peyrony O, Chumbita M, Aiello TF, Monzo-Gallo P, Lopera C, Puerta-Alcalde P, Magnano L, Martinez-Cibrian N, Pitart C, Juan M, Delgado J, Fernandez De Larrea C, Soriano Á, Urbano-Ispizua Á, Garcia-Vidal C. Garcia-Pouton N, et al. Among authors: juan m. Eur J Haematol. 2024 Mar;112(3):371-378. doi: 10.1111/ejh.14122. Epub 2023 Oct 25. Eur J Haematol. 2024. PMID: 37879842
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
Díez-Alonso L, Falgas A, Arroyo-Ródenas J, Romencín PA, Martínez A, Gómez-Rosel M, Blanco B, Jiménez-Reinoso A, Mayado A, Pérez-Pons A, Aguilar-Sopeña Ó, Ramírez-Fernández Á, Segura-Tudela A, Perez-Amill L, Tapia-Galisteo A, Domínguez-Alonso C, Rubio-Pérez L, Jara M, Solé F, Hangiu O, Almagro L, Albitre Á, Penela P, Sanz L, Anguita E, Valeri A, García-Ortiz A, Río P, Juan M, Martínez-López J, Roda-Navarro P, Martín-Antonio B, Orfao A, Menéndez P, Bueno C, Álvarez-Vallina L. Díez-Alonso L, et al. Among authors: juan m. Sci Transl Med. 2024 Feb 14;16(734):eadg7962. doi: 10.1126/scitranslmed.adg7962. Epub 2024 Feb 14. Sci Transl Med. 2024. PMID: 38354229
Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation.
Betriu S, Rovira J, Arana C, García-Busquets A, Matilla-Martinez M, Ramirez-Bajo MJ, Bañon-Maneus E, Lazo-Rodriguez M, Bartoló-Ibars A, Claas FHJ, Mulder A, Heidt S, Juan M, Bayés-Genís B, Campistol JM, Palou E, Diekmann F. Betriu S, et al. Among authors: juan m. HLA. 2023 Oct;102(4):449-463. doi: 10.1111/tan.15156. Epub 2023 Jul 28. HLA. 2023. PMID: 37503860
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, Angelats L, Modrego-Sanchez A, Sanfeliu E, Castillo O, Blasco P, Mezquita L, Viñolas N, Nogué M, Galván P, Adamo B, Basté N, Sauri T, Juan M, Prat A, Schettini F. García-Corbacho J, et al. Among authors: juan m. Cancer Immunol Immunother. 2023 Jun;72(6):1709-1723. doi: 10.1007/s00262-022-03360-9. Epub 2023 Jan 10. Cancer Immunol Immunother. 2023. PMID: 36625938 Free PMC article.
Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, Angelats L, Modrego-Sanchez A, Sanfeliu E, Castillo O, Blasco P, Mezquita L, Viñolas N, Nogué M, Galván P, Adamo B, Basté N, Sauri T, Juan M, Prat A, Schettini F. García-Corbacho J, et al. Among authors: juan m. Cancer Immunol Immunother. 2023 Jun;72(6):1725-1726. doi: 10.1007/s00262-023-03396-5. Cancer Immunol Immunother. 2023. PMID: 36809405 Free PMC article. No abstract available.
525 results